MTOR and rhabdomyosarcoma: This is demonstrated well by the fact that only 5.4% of rhabdomyosarcomas have an activating mutation in the PIK3CA gene, but whole-genome, whole-exome and transcriptome sequencing on 44 rhabdomyosarcoma samples identified dysregulation of the PI3K/AKT/mTOR pathway by upstream receptor kinase regulators in 93% of samples [16].